JP2003505343A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003505343A5 JP2003505343A5 JP2001501237A JP2001501237A JP2003505343A5 JP 2003505343 A5 JP2003505343 A5 JP 2003505343A5 JP 2001501237 A JP2001501237 A JP 2001501237A JP 2001501237 A JP2001501237 A JP 2001501237A JP 2003505343 A5 JP2003505343 A5 JP 2003505343A5
- Authority
- JP
- Japan
- Prior art keywords
- botulinum
- complex
- counterpart
- medicament
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19925739.6 | 1999-06-07 | ||
| DE19925739A DE19925739A1 (de) | 1999-06-07 | 1999-06-07 | Therapeutikum mit einem Botulinum-Neurotoxin |
| PCT/DE2000/001777 WO2000074703A2 (de) | 1999-06-07 | 2000-05-26 | Therapeutikum mit einem botulinum-neurotoxin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007130686A Division JP2007238627A (ja) | 1999-06-07 | 2007-05-16 | ボツリヌス神経毒を含む治療薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003505343A JP2003505343A (ja) | 2003-02-12 |
| JP2003505343A5 true JP2003505343A5 (https=) | 2007-06-28 |
Family
ID=7910318
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001501237A Pending JP2003505343A (ja) | 1999-06-07 | 2000-05-26 | ボツリヌス神経毒を含む治療薬 |
| JP2007130686A Withdrawn JP2007238627A (ja) | 1999-06-07 | 2007-05-16 | ボツリヌス神経毒を含む治療薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007130686A Withdrawn JP2007238627A (ja) | 1999-06-07 | 2007-05-16 | ボツリヌス神経毒を含む治療薬 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US7964199B1 (https=) |
| EP (1) | EP1185291B2 (https=) |
| JP (2) | JP2003505343A (https=) |
| KR (1) | KR100466407B1 (https=) |
| CN (2) | CN101062009A (https=) |
| AR (1) | AR024306A1 (https=) |
| AT (1) | ATE258803T1 (https=) |
| AU (1) | AU774590B2 (https=) |
| CA (1) | CA2376193C (https=) |
| CO (1) | CO5170431A1 (https=) |
| CZ (1) | CZ20014351A3 (https=) |
| DE (3) | DE19925739A1 (https=) |
| DK (1) | DK1185291T3 (https=) |
| EA (1) | EA004202B1 (https=) |
| ES (1) | ES2215056T5 (https=) |
| GE (1) | GEP20043200B (https=) |
| HU (1) | HUP0201530A3 (https=) |
| IL (2) | IL146974A0 (https=) |
| MX (1) | MXPA01012540A (https=) |
| NO (1) | NO20015964L (https=) |
| PL (1) | PL198958B1 (https=) |
| PT (1) | PT1185291E (https=) |
| TW (1) | TWI251492B (https=) |
| UA (1) | UA72253C2 (https=) |
| WO (1) | WO2000074703A2 (https=) |
| ZA (1) | ZA200110074B (https=) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19925739A1 (de) | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
| US20080038274A1 (en) | 1999-09-23 | 2008-02-14 | Foster Keith A | Inhibition of secretion from non-neuronal cells |
| US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| US7838007B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating mammary gland disorders |
| US6821520B2 (en) | 2000-02-15 | 2004-11-23 | Allergan, Inc. | Clostridial toxin therapy for Hashimoto's thyroiditis |
| JP2003009897A (ja) | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
| US7140371B2 (en) | 2002-03-14 | 2006-11-28 | Allergan, Inc. | Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins |
| US6688311B2 (en) | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
| WO2003082315A1 (fr) * | 2002-03-29 | 2003-10-09 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Remede contre l'hypermyotonie |
| US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
| US20120114697A1 (en) | 2002-08-19 | 2012-05-10 | Ira Sanders | Treatment of holocrine gland dysfunction with clostridia neurotoxins |
| US7288259B2 (en) * | 2002-08-19 | 2007-10-30 | Ira Sanders | Treatment of holocrine gland dysfunction with clostridia neurotoxins |
| US7824693B2 (en) | 2002-08-19 | 2010-11-02 | Ira Sanders | Treatment of fine wrinkles with clostridia neurotoxins |
| US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
| ES2381091T3 (es) * | 2003-03-06 | 2012-05-23 | Botulinum Toxin Research Associates, Inc. | Tratamiento del dolor facial crónico y cefalea relacionados con la sinusitis con toxina botulínica |
| US6838434B2 (en) * | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
| WO2004112821A1 (ja) * | 2003-06-20 | 2004-12-29 | Santen Pharmaceutical Co., Ltd. | 筋緊張亢進性疾患の治療剤 |
| US6974579B2 (en) * | 2004-01-08 | 2005-12-13 | Allergan, Inc. | Methods for treating vascular disorders |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| CA2558676C (en) | 2004-03-03 | 2019-04-16 | Essentia Biosystems, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
| CN1946431B (zh) | 2004-03-03 | 2011-12-07 | 雷文斯治疗公司 | 用于肉毒毒素的局部施用和透皮递送的组合物和方法 |
| GB2416122A (en) * | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
| BRPI0513850A (pt) * | 2004-07-26 | 2008-05-20 | Merz Pharma Gmbh & Co Kgaa | composição terapêutica com uma neurotoxina botulìnica |
| US7179474B2 (en) | 2004-09-03 | 2007-02-20 | Allergan, Inc. | Methods for treating a buttock deformity |
| US7429386B2 (en) | 2004-09-03 | 2008-09-30 | Allergan, Inc. | Stretch mark treatment |
| AU2005288758A1 (en) * | 2004-09-27 | 2006-04-06 | Merz Pharma Gmbh & Co. Kgaa | Clostridial neurotoxins for use in tissue healing |
| SG160357A1 (en) | 2005-03-03 | 2010-04-29 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| WO2006096163A1 (en) * | 2005-03-03 | 2006-09-14 | Allergan, Inc. | Animal product free system and process for purifying a botulinum toxin |
| US7419675B2 (en) | 2005-05-26 | 2008-09-02 | Allergan, Inc. | Method for treating peritoneal adhesions |
| HRP20090382T1 (hr) * | 2005-06-17 | 2009-09-30 | Merz Pharma Gmbh & Co.Kgaa | Uređaj i postupak za proizvodnju biološko aktivnih spojeva fermentacijom |
| NZ568216A (en) | 2005-11-17 | 2012-09-28 | Revance Therapeutics Inc | Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins |
| EP1834962A1 (de) * | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
| US10792344B2 (en) | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
| EP2048156A1 (en) * | 2007-10-12 | 2009-04-15 | Merz Pharma GmbH & Co.KGaA | Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin |
| CA2686642A1 (en) * | 2007-06-01 | 2008-12-04 | Merz Pharma Gmbh & Co. Kgaa | Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin |
| DE102007038015A1 (de) * | 2007-08-10 | 2009-02-19 | Hefter, Harald, Prof. Dr. med. Dr. rer. nat. | Verwendung eines Neurotoxins |
| US9161970B2 (en) * | 2007-12-12 | 2015-10-20 | Allergan, Inc. | Dermal filler |
| EP2072039A1 (en) | 2007-12-21 | 2009-06-24 | Merz Pharma GmbH & Co.KGaA | Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects |
| EP2072057A1 (en) | 2007-12-21 | 2009-06-24 | Merz Pharma GmbH & Co.KGaA | Early administration of Botulinum toxin in the treatment of cerebrovascular event and spinal cord injury |
| EP2246426A4 (en) * | 2008-01-29 | 2011-08-10 | Inst Antibodies Co Ltd | COMPOSITION FOR THE NEUTRALIZATION OF BOTULINUS TOXIN TYPE-A AND HUMAN ANTIBODIES AGAINST BOTULINUS TOXIN TYPE-A |
| US9107815B2 (en) * | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
| PL2271670T3 (pl) * | 2008-03-14 | 2015-05-29 | Allergan Inc | Testy aktywności serotypu A toksyny botulinowej oparte na immunologii |
| WO2009123174A1 (ja) * | 2008-03-31 | 2009-10-08 | 財団法人化学及血清療法研究所 | A2型ボツリヌス神経毒素製剤 |
| EP2337790B1 (en) | 2008-08-29 | 2016-07-13 | Merz Pharma GmbH & Co. KGaA | Clostridial neurotoxins with altered persistency |
| ES2426667T3 (es) | 2008-09-09 | 2013-10-24 | Susanne Grafe | Toxina botulínica para introducir infertilidad temporal en un vertebrado (por ejemplo, un ser humano) |
| CN101386648B (zh) * | 2008-09-25 | 2012-05-30 | 中国人民解放军军事医学科学院微生物流行病研究所 | 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途 |
| WO2010096134A1 (en) | 2008-12-04 | 2010-08-26 | Botulinum Toxin Research Associates, Inc. | Extended length botulinum toxin formulation for human or mammalian use |
| EP2248518B1 (en) | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
| US8129139B2 (en) | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
| JP2011074025A (ja) * | 2009-09-30 | 2011-04-14 | Chemo-Sero-Therapeutic Research Inst | ボツリヌス毒素の精製方法 |
| PH12012500549A1 (en) | 2009-10-21 | 2017-08-23 | Revance Therapeutics Inc | Methods and systems for purifying non-complexed botulinum neurotoxin |
| KR101134146B1 (ko) | 2010-05-31 | 2012-04-19 | 메덱스젠 주식회사 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
| JP5990176B2 (ja) | 2010-10-12 | 2016-09-07 | メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン | タンパク質の安定化に好適な哺乳動物性賦形剤非含有製剤 |
| EP2724725B1 (en) * | 2011-06-27 | 2016-09-07 | Sang Duck Kim | Pharmaceutical composition for use in treating scars on the skin |
| US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
| KR102272580B1 (ko) * | 2013-07-30 | 2021-07-05 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 독소의 고순도 신경독성 성분의 제조 방법 및 이의 용도 |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US20180140685A1 (en) * | 2015-04-24 | 2018-05-24 | Consiglio Nazionale Delle Ricerche | A new therapeutic use of the botulinum neurotoxin serotype a |
| KR101775682B1 (ko) * | 2015-11-30 | 2017-09-06 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
| BR112019004935A2 (pt) | 2016-09-13 | 2019-06-04 | Allergan, Inc. | composições de toxina clostridial não proteíca estabilizada |
| KR102463881B1 (ko) | 2016-10-04 | 2022-11-07 | (주)메디톡스 | 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법 |
| JP7604222B2 (ja) | 2017-03-22 | 2024-12-23 | ボンチ インコーポレイテッド | 治療用のボツリヌス神経毒素 |
| BR112019016585A2 (pt) | 2017-03-24 | 2020-03-31 | Merz Pharma Gmbh & Co. Kgaa | Uso melhorado da neurotoxina botulínica no tratamento da sialorreia |
| EP3843777A4 (en) | 2018-08-28 | 2022-05-04 | Ira Sanders | THERAPEUTICS FOR THE SKIN |
| EP3860640A1 (en) | 2018-10-02 | 2021-08-11 | Merz Pharma GmbH & Co. KGaA | Novel uses of botulinum neurotoxin for treating lipoedema |
| MX2021009922A (es) | 2019-02-21 | 2021-09-14 | Merz Pharma Gmbh & Co Kgaa | Usos novedosos de neurotoxina botulinica para el tratamiento del temblor. |
| IL298399A (en) | 2020-06-05 | 2023-01-01 | Merz Pharma Gmbh & Co Kgaa | Treatment of facial wrinkles with the botulinum toxin in high dose and low volume |
| KR102724651B1 (ko) * | 2021-07-08 | 2024-11-01 | 주식회사 파마리서치바이오 | 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법 |
| TW202400122A (zh) | 2022-02-28 | 2024-01-01 | 德商梅茲製藥有限兩合公司 | 肉毒桿菌毒素用於降低皮膚毛孔尺寸及／或皮脂產生之用途、以及降低皮膚毛孔尺寸及／或皮脂產生的方法 |
| EP4626556A1 (en) | 2022-11-28 | 2025-10-08 | Merz Pharma GmbH & Co. KGaA | High concentration botulinum toxin treatment for neck rejuvenation |
| AU2023400491A1 (en) | 2022-11-28 | 2025-04-10 | Merz Pharma Gmbh & Co. Kgaa | Botulinum toxin injection in platysma for lower face and neck rejuvenation |
| WO2024194181A1 (en) | 2023-03-20 | 2024-09-26 | Merz Therapeutics GmbH | Nh3 scavenger for use in the treatment of mobility disability in a post-stroke patient |
| WO2024240868A1 (en) | 2023-05-23 | 2024-11-28 | Merz Therapeutics GmbH | Botulinum toxin for treating peripheral neuropathic pain |
| KR20260035809A (ko) | 2023-07-12 | 2026-03-13 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 독소에 의한 과색소침착 상태의 치료 |
| WO2025228877A1 (en) | 2024-04-29 | 2025-11-06 | Merz Therapeutics GmbH | Botulinum toxin for the preventive treatment of migraine |
| WO2026021713A1 (en) | 2024-07-23 | 2026-01-29 | Merz Therapeutics GmbH | Uses of magnetic nerve stimulation associated with botulinum neurotoxin administration |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2236692T3 (es) | 1993-05-14 | 2005-07-16 | Stephen S Arnon | Un metodo para prevenir los efectos secundarios y la insensibilidad a los usos terapeuticos de toxinas. |
| JP4249802B2 (ja) | 1993-06-10 | 2009-04-08 | アラーガン、インコーポレイテッド | 神経筋疾患および症状を処置するためのボツリヌス毒素組み合わせ |
| ES2332905T3 (es) | 1993-12-28 | 2010-02-15 | Allergan, Inc. | Uso del componente neurotoxico de la toxina botulinica para el tratamiento de trastornos de musculos lisos. |
| US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| PT1086702E (pt) | 1994-05-09 | 2005-08-31 | William J Binder | Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca |
| WO1996005222A1 (en) | 1994-08-08 | 1996-02-22 | Wisconsin Alumni Research Foundation | Purification and pharmaceutical compositions containing type g botulinum neurotoxin |
| US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| US5756468A (en) | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
| DE69627963T2 (de) * | 1995-06-06 | 2004-03-04 | Pearce, L. Bruce, Cambridge | Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen |
| US5939070A (en) * | 1996-10-28 | 1999-08-17 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
| EP1011695B2 (en) * | 1997-07-15 | 2009-11-04 | The Regents of the University of Colorado | Use of neurotoxin therapy for treatment of prostate disorders |
| TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
| DE19856897A1 (de) * | 1998-12-10 | 2000-06-15 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum zur Unterdrückung von Schnarchgeräuschen |
| DE19925739A1 (de) | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
| US6358917B1 (en) * | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
| US6787517B1 (en) * | 2000-12-29 | 2004-09-07 | Allergan, Inc. | Agent and methods for treating pain |
| DE10333317A1 (de) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
| BRPI1014253A2 (pt) * | 2009-07-02 | 2016-04-12 | Merz Pharma Gmbh & Co Kgaa | polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento |
-
1999
- 1999-06-07 DE DE19925739A patent/DE19925739A1/de not_active Withdrawn
-
2000
- 2000-05-26 MX MXPA01012540A patent/MXPA01012540A/es active IP Right Grant
- 2000-05-26 AT AT00943666T patent/ATE258803T1/de active
- 2000-05-26 EA EA200200017A patent/EA004202B1/ru not_active IP Right Cessation
- 2000-05-26 CN CNA2007101102394A patent/CN101062009A/zh active Pending
- 2000-05-26 DE DE10081516T patent/DE10081516D2/de not_active Ceased
- 2000-05-26 DK DK00943666T patent/DK1185291T3/da active
- 2000-05-26 IL IL14697400A patent/IL146974A0/xx active IP Right Grant
- 2000-05-26 EP EP00943666A patent/EP1185291B2/de not_active Expired - Lifetime
- 2000-05-26 AU AU58047/00A patent/AU774590B2/en not_active Ceased
- 2000-05-26 DE DE50005208T patent/DE50005208D1/de not_active Expired - Lifetime
- 2000-05-26 CN CNB008086419A patent/CN100389820C/zh not_active Expired - Fee Related
- 2000-05-26 CZ CZ20014351A patent/CZ20014351A3/cs unknown
- 2000-05-26 WO PCT/DE2000/001777 patent/WO2000074703A2/de not_active Ceased
- 2000-05-26 HU HU0201530A patent/HUP0201530A3/hu unknown
- 2000-05-26 CA CA002376193A patent/CA2376193C/en not_active Expired - Fee Related
- 2000-05-26 JP JP2001501237A patent/JP2003505343A/ja active Pending
- 2000-05-26 US US10/018,373 patent/US7964199B1/en not_active Expired - Lifetime
- 2000-05-26 ES ES00943666T patent/ES2215056T5/es not_active Expired - Lifetime
- 2000-05-26 KR KR10-2001-7015668A patent/KR100466407B1/ko not_active Expired - Fee Related
- 2000-05-26 UA UA2002010181A patent/UA72253C2/uk unknown
- 2000-05-26 PT PT00943666T patent/PT1185291E/pt unknown
- 2000-05-26 GE GEAP20006278A patent/GEP20043200B/en unknown
- 2000-05-26 PL PL352468A patent/PL198958B1/pl not_active IP Right Cessation
- 2000-06-07 AR ARP000102818A patent/AR024306A1/es unknown
- 2000-06-07 CO CO00042309A patent/CO5170431A1/es not_active Application Discontinuation
- 2000-08-24 TW TW089111212A patent/TWI251492B/zh not_active IP Right Cessation
-
2001
- 2001-12-06 IL IL146974A patent/IL146974A/en not_active IP Right Cessation
- 2001-12-06 NO NO20015964A patent/NO20015964L/no unknown
- 2001-12-06 ZA ZA200110074A patent/ZA200110074B/xx unknown
-
2007
- 2007-05-16 JP JP2007130686A patent/JP2007238627A/ja not_active Withdrawn
-
2011
- 2011-05-11 US US13/068,439 patent/US20110217287A1/en not_active Abandoned
- 2011-11-23 US US13/303,973 patent/US8398998B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003505343A5 (https=) | ||
| CY2020003I2 (el) | Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn | |
| AT500379B8 (de) | Tau-proteine | |
| CY1110128T1 (el) | Καταλυτικα μονοκλωνικα αντισωματα με δραστικοτητα πρωτεασης για την εκλεκτικη λυση του πρωτεϊνικου συστατικου των πλακων και συνονθυλευματων που σχετιζονται με παθολογικες καταστασεις | |
| ATE376559T1 (de) | Methoden der verhinderung und behandlung der alzheimer'schen krankheit | |
| WO2001089457A3 (en) | Thrombopoietin mimetics | |
| WO2002094228A8 (en) | Prevention and treatment of allergies by helminthic regulation of ige | |
| WO2001098317A3 (en) | Alpha-glycosylceramides for treating bacterial and fungal infections | |
| JP2001515920A5 (https=) | ||
| ATE419872T1 (de) | Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene | |
| ATE425248T1 (de) | Arzneimittel zur behandlung von c. pneumoniae infektionen | |
| ATE319439T1 (de) | Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd | |
| WO2003005880A3 (en) | Replikin peptides and uses thereof | |
| ATE310088T1 (de) | Behandlung und nachweis von staphylokokkeninfektionen | |
| DE69530844D1 (de) | Verfahren und substanzen gegen protozoen | |
| EP1610678A4 (en) | ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF FOR INHIBITING THE ACTIVITY OF METAL PROTEINS | |
| JP2003533188A5 (https=) | ||
| WO2007021886A3 (en) | Truncated memapsin 2 for use for treating alzheimer's disease | |
| ATE369429T1 (de) | Strukturproteine des virus, welches die pankreas- krankheit bei fischen verursacht, und ihre verwendungen | |
| WO2002055560A3 (en) | Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c | |
| EP2436774A3 (en) | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins | |
| DE69502380D1 (de) | 4-aminoderivate von 5-substituierten mycophenolsäuren | |
| DE60124093D1 (de) | S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen. | |
| BR0317780A (pt) | Formulação na forma de supositório para a administração retal, método para o tratamento de hemorróidas, e uso de peptìdeos e proteìnas com ação trombolìtica para o tratamento de hemorróidas | |
| WO2002029023A8 (en) | Nicastrin protein |